Загрузка...
Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
Osteoporosis is age-related deterioration in bone mass and micro-architecture. Denosumab is a novel human monoclonal antibody for osteoporosis. It is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, which binds to and inhibits osteoblast-produced RANKL, in turn reduces the binding...
Сохранить в:
| Опубликовано в: : | Front Cell Dev Biol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7240042/ https://ncbi.nlm.nih.gov/pubmed/32478071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.00325 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|